Synergy Pharma (SGYP) Posts Q1 Loss of 18c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Aegis Trims PT on Synergy (SGYP) to $26 Following Q1 Results; Updates on N-T Catalysts
May 14, 2014 10:02 AM EDTAegis Capital cuts its price target on Synergy Pharmaceuticals (Nasdaq: SGYP) from $28 down to $26 while affirming its Buy rating.
Analyst Ram Selvaraju noted that Synergy's Q1 loss of $.18 per share was narrower than his expected loss of $.23 per share, based on lower R&D and G&A spending.
Selvaraju also highlighted near-term catalysts for... More
